Genmab — Maj 2017
-
Det er nogle hidsige papirer.
-
• USD 255 million in net sales of DARZALEX
(daratumumab); resulting in royalty income of DKK 211 million
• DARZALEX received positive opinion from European regulatory authorities for relapsed or refractory multiple myeloma
• Judith Klimovsky, MD appointed Chief Development Officer
• Phase II study of daratumumab in non-Hodgkin's lymphoma (CARINA) did not proceed to stage 2 of trial -
Jeg er tungt lastet i Bullx4....dejligt. Rigtigt Helge, men er man lidt heldig og lidt dygtig kom man også igennem den periode
-
enmab fastholder forventningerne til 2017
17:04
Genmab fastholder forventningerne til 2017 om en omsætning i intervallet 1950-2150 mio. kr. og et driftsoverskud på 900-1100 mio. kr.Det fremgår af selskabets regnskab for første kvartal af 2017.
ritzau/FINANS
-
-
Har også en portion Bull x4 .... sådan en dag som idag er gode vitaminer for disse
-
Mon ikke de skal ud og købe nogle Genmab? http://penge.borsen.dk/artikel/1/345066/aktier_investorerne_traeder_paa_bremsen_i_usa.html
-
@ Helge herlig læsning. Bliver interessant når de næste salgstal foreligger. Hvornår er det de forventes, 24 Maj?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind